Compare Sana Biotechnology Inc (SANA) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Verizon Communications Inc — how do they compare? Sana Biotechnology Inc trades at $3.24 (market cap $1.03B), while Verizon Communications Inc trades at $49.93 (market cap $209.44B). The key difference: Verizon Communications Inc is far larger — about 203.3× Sana Biotechnology Inc's market cap, and Verizon Communications Inc pays a 5.61% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | VZ | |
|---|---|---|
Market Cap | $1.03B | $209.44B |
Sector | Health | Media |
52-Week High | $5.92 | $51.38 |
52-Week Low | $2.68 | $38.40 |
Enterprise Value | $946.04M | $396.15B |
Volume | — | 22,584,735 |
Dividend Yield | — | 5.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Verizon (VZ) trades at $50.41, up 0.54% today, with a bullish technical signal and consistent earnings beats in recent quarters. The stock offers a 5%+ dividend yield, supported by strong cash flow and a P/E of 13.13. Recent news highlights growth in broadband and AI infrastructure, including a multi-billion dollar fiber deal with Corning.
Outlook is positive with cost discipline and shareholder returns, but risks include high debt and competitive pressures. Analysts are mixed with a $49.69 consensus target, slightly below current price, indicating cautious optimism amid execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
